Clinical Trials in Boston

Showing 421-440 of 17,836 trials

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

NCT06315023

The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.

Peripheral Arterial DiseaseSymptomatic Femoropopliteal Lesions

Endologix450 participantsStarted Oct 2023

Salinas, California, United States • Storrs, Connecticut, United States • Washington D.C., District of Columbia, United States +7 more locations

RECRUITINGPhase 3< 1 mile

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

Relapsing Multiple Sclerosis

Novartis Pharmaceuticals360 participantsStarted Jul 2025

Scottsdale, Arizona, United States • Washington D.C., District of Columbia, United States • Altamonte Springs, Florida, United States +99 more locations

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Find Trials by Condition in Boston

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Management of the PDA Trial

The Ailliance Post-Market Clinical Study

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)